Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Pacira Drug Promotion Suit Settled With Broad Concessions From FDA

This article was originally published in The Gray Sheet

Executive Summary

The agency will formally rescind Exparel warning letter and expand labeling to clarify that pain drug is not limited to any specific surgery. The drug case has been closely watched for implications on FDA's oversight of off-label communications for both drugs and devices.

Advertisement

Related Content

FDA Seeks To Resolve First Amendment Suit By Pacira

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

MT034475

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Add a personalized Question to your Analyst

Cancel